|Bid||2.4000 x 0|
|Ask||2.5000 x 0|
|Day's Range||2.4000 - 2.5100|
|52 Week Range||2.4000 - 6.9000|
|Beta (3Y Monthly)||1.56|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.50|
Every investor in Correvio Pharma Corp. (TSE:CORV) should be aware of the most powerful shareholder groups. Insiders...
VANCOUVER , June 24, 2019 /CNW/ - Correvio Pharma Corp. (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Brinavess™ (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of adult patients with recent onset atrial fibrillation (AF). "The resubmission of the Brinavess NDA is a major milestone for Correvio and is the culmination of substantial effort by our employees and the investigators who have dedicated themselves toward investigating this potential new treatment option for adult patients with recent onset AF," said Mark H.N. Corrigan , MD, CEO of Correvio.
Statistically speaking, long term investing is a profitable endeavour. But no-one is immune from buying too high...
On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 23 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by ...
Conference Call Scheduled for Wednesday, May 8, 2019 at 8:30 a.m. Eastern ( 5:30 a.m. Pacific) NASDAQ: CORV TSX: CORV VANCOUVER , May 1, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: ...
NASDAQ: CORV TSX: CORV Seven Data Abstracts Selected for Poster Presentations VANCOUVER , April 3, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company ...
VANCOUVER, March 20, 2019 /PRNewswire/ - Correvio Pharma Corp. (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced the presentation of new Brinavess® (vernakalant hydrochloride, IV) data at the American College of Cardiology 2019 Annual Meeting taking place March 16-18, 2019, in New Orleans. This poster presentation highlights reduced hospitalization in patients treated with Brinavess, Correvio's antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), from a clinical survey assessing patients with acute AF at the Hillel Yaffe Medical Center located in Hadera, Israel. This presentation, titled "Intravenous Vernakalant for the Treatment of New-Onset Atrial Fibrillation in the Emergency Department," was given by Jameel Mohsen, MD, Hillel Yaffe Medical Center.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are moreRead More...
VANCOUVER, March 14, 2019 /PRNewswire/ - Correvio Pharma Corp. (CORV) (CORV), ("Correvio" or the "Company"), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has entered into an At the Market Sales Issuance Agreement dated March 13, 2019 (the "Sales Agreement") with Cantor Fitzgerald & Co. ("Cantor") as agent, pursuant to which the Company may, from time to time sell, through "at-the-market" offerings on the Nasdaq Capital Market or another existing trading market in the United States with Cantor as agent, such number of common shares as would have an aggregate offer price of up to US$50,000,000 subject to a limit of US$12,000,000 under the ATM Prospectus Supplement (as defined below). Cantor, at Correvio's discretion and instruction, will use its commercially reasonable efforts to sell the common shares at market prices from time to time.